| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
NovaBridge Biosciences
13D/A
NBP · 44975P103
|
11.5% |
2/3/2026
Event 1/29/2026
|
||||
| CBC Investment I-Mab Limited | 4.4% | |||||
| IBC Investment Seven Limited | 1.4% | |||||
| CBC Spvii Limited | 2.1% | |||||
| C-Bridge II Investment Ten Limited | 0.9% | |||||
| Nova Aqua Limited | 2.7% | |||||
| C-Bridge Healthcare Fund II, L.P. | 5.3% | |||||
| C-Bridge Healthcare Fund GP II, L.P. | 5.3% | |||||
| C-Bridge Capital GP, Ltd. | 8.8% | |||||
| I-Bridge Healthcare Fund, L.P. | 3.5% | |||||
| I-Bridge Healthcare GP, L.P. | 3.5% | |||||
| I-Bridge Capital GP, Ltd. | 3.5% | |||||
| Wei Fu | 11.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.